z-logo
open-access-imgOpen Access
Long lasting octreotide LAR therapy in non functioning pancreatic neuroendocrine carcinoma
Author(s) -
Ivan Lolli,
Antonio Logroscino,
Simona Vallarelli,
Maria A. Monteduro,
Antonella Gentile,
G Troccoli
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i1s.1067
Subject(s) - medicine , octreotide , endocrine system , somatostatin receptor , somatostatin , gastroenterology , disease , hormone , oncology
Non functioning endocrine pancreatic tumors (NF-PETs) have absent or low hormone secretion without symptoms and constitue ~60% of PETs. At diagnosis more than 50% of patients have liver metastases and almost 40% are not candidates for radical surgery because of either locally advanced disease or unresectable metastases. We described the case of a 47-year-old woman with a pancreatic carcinoma with secondarism in the liver not suitable for radical surgery. Histological test of liver metastases showed positivity for endocrine well-differentiated non functioning carcinoma expressing receptors for somatostatin with very low proliferation index (Ki67 < 2%). After this diagnosis she started a specific treatment with octreotide analogues which achieved durable stabilization of the disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here